These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 39234260)

  • 1. Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.
    Shan Z; Liu F
    Front Immunol; 2024; 15():1441410. PubMed ID: 39234260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in immunotherapy in cancer treatment.
    Patel AA
    Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):89-99. PubMed ID: 38814230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy.
    Knight AD; Luke JJ
    Curr Oncol Rep; 2024 Jul; 26(7):826-839. PubMed ID: 38789670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
    Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X
    Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
    Babacan NA; Eroglu Z
    Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal Melanoma: a Literature Review.
    Yde SS; Sjoegren P; Heje M; Stolle LB
    Curr Oncol Rep; 2018 Mar; 20(3):28. PubMed ID: 29569184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma immunotherapy: strategies to overcome pharmacological resistance.
    Trojaniello C; Vitale MG; Scarpato L; Esposito A; Ascierto PA
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):289-304. PubMed ID: 32195606
    [No Abstract]   [Full Text] [Related]  

  • 11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
    Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():1956. PubMed ID: 32983126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
    Christiansen SA; Khan S; Gibney GT
    Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancements in Melanoma Therapies: From Surgery to Immunotherapy.
    Shajari N; Baradaran B; Tohidkia MR; Nasiri H; Sepehri M; Setayesh S; Aghebati-Maleki L
    Curr Treat Options Oncol; 2024 Aug; 25(8):1073-1088. PubMed ID: 39066854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Therapies for Melanoma.
    Buchbinder EI
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging insights into thyroid cancer from immunotherapy perspective: A bibliometric analysis.
    Wang Q; Pan G; Zhang Y; Ni Y; Mu Y; Luo D
    Hum Vaccin Immunother; 2024 Dec; 20(1):2403170. PubMed ID: 39294892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
    McKenzie JA; Mbofung RM; Malu S; Zhang M; Ashkin E; Devi S; Williams L; Tieu T; Peng W; Pradeep S; Xu C; Zorro Manrique S; Liu C; Huang L; Chen Y; Forget MA; Haymaker C; Bernatchez C; Satani N; Muller F; Roszik J; Kalra A; Heffernan T; Sood A; Hu J; Amaria R; Davis RE; Hwu P
    J Natl Cancer Inst; 2018 Jul; 110(7):777-786. PubMed ID: 29267866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
    Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.